AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9817708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 500 micrograms ipratropium bromide (IB)
Number of subjects: 29
Study 9817708 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (P)
Number of subjects: 29
Study 7714223 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 11,939, 32 mg thrice daily
Number of subjects: 72
Study 7714223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 2496225 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide alone
Number of subjects: 11
Study 2496225 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide during chronic treatment with low dose quinidine (50 mg q 6 hr)
Number of subjects: 11
Study 2496225 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide plus quinidine in extensive metabolizers
Number of subjects: 11
Study 2496225 — intervention group
Group type: COMPARATOR
Intervention: Encainide plus quinidine in poor metabolizers
Number of subjects: 11
Study 152681 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone, 200 mg daily
Number of subjects: 5
Study 31488177 — intervention group
Group type: EXPERIMENTAL
Intervention: One-staged hip and knee arthroplasty (group A)
Number of subjects: 42
Study 31488177 — intervention group
Group type: COMPARATOR
Intervention: Two-staged hip and knee arthroplasty (group B)
Number of subjects: 42
Study 26541328 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-enriched virgin olive oil containing a mixture of 500 mg PC/kg from OO and thyme (FVOOT)
Number of subjects: 12
Study 26541328 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-enriched virgin olive oil containing 500 mg PC/kg from OO (FVOO)
Number of subjects: 12
Study 26541328 — intervention group
Group type: COMPARATOR
Intervention: Virgin olive oil naturally containing 80 mg PC/kg (VOO)
Number of subjects: 12
Study 26349830 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (2 g) and RPX7009 (2 g) administered every 8 h as a 3-h intravenous infusion for a total of three doses
Number of subjects: 25
Study 22657748 — intervention group
Group type: EXPERIMENTAL
Intervention: STAGE‐12 intervention
Number of subjects: 471
Study 22657748 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 471
Study 21306324 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian diathermy (LOD)
Number of subjects: 44
Study 19941250 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 43
Study 19941250 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 16758046 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin 10 mg daily and analgesic (indomethacin) for a maximum of 4 weeks
Number of subjects: 64
Study 16758046 — intervention group
Group type: COMPARATOR
Intervention: Analgesic only (control group)
Number of subjects: 64
Study 15660196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine treatment
Number of subjects: 93
Study 15660196 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet and exercise
Number of subjects: 93
Study 11318047 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified versions of simple, go/no-go, and choice reaction time tasks
Number of subjects: 0
Study 9388047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine (NIL)
Number of subjects: 36
Study 9388047 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocapril (TEM)
Number of subjects: 36
Study 9388047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine (CAD)
Number of subjects: 36
Study 7955922 — intervention group
Group type: EXPERIMENTAL
Intervention: New untreated PT
Number of subjects: 46
Study 7955922 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated PT
Number of subjects: 46
Study 7955922 — intervention group
Group type: COMPARATOR
Intervention: Reactive thrombocytosis (RT)
Number of subjects: 46
Study 3307653 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 57
Study 3307653 — intervention group
Group type: COMPARATOR
Intervention: Shunt surgery
Number of subjects: 57
Study 31762185 — intervention group
Group type: EXPERIMENTAL
Intervention: Leopold's maneuvers administered in the 28th week of pregnancy and re-administered in the 32nd and 36th weeks.
Number of subjects: 100
Study 31762185 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention during the same weeks.
Number of subjects: 100
Study 28575286 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (IIV) during pregnancy
Number of subjects: 2049
Study 28575286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2049
Study 25528125 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental tobacco control intervention
Number of subjects: 17692
Study 25528125 — intervention group
Group type: COMPARATOR
Intervention: Control group practices
Number of subjects: 17692
Study 22311006 — intervention group
Group type: EXPERIMENTAL
Intervention: Welding fumes exposure at 1 mg/m(3) for 6 hours
Number of subjects: 12
Study 22311006 — intervention group
Group type: EXPERIMENTAL
Intervention: Welding fumes exposure at 2.5 mg/m(3) for 6 hours
Number of subjects: 12
Study 22311006 — intervention group
Group type: COMPARATOR
Intervention: Ambient air exposure (0 mg/m(3)) for 6 hours
Number of subjects: 12
Study 21696537 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 31
Study 21696537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 18359422 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving new antibiotics during the surveillance period
Number of subjects: 739
Study 18359422 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients not on antibiotics
Number of subjects: 739
Study 18359422 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients on no new antibiotics
Number of subjects: 739
Study 18359422 — intervention group
Group type: COMPARATOR
Intervention: Pre-enrollment cultures
Number of subjects: 739
Study 18359422 — intervention group
Group type: COMPARATOR
Intervention: Potential antibiotic error rates
Number of subjects: 739
Study 16946611 — intervention group
Group type: EXPERIMENTAL
Intervention: Weissella cibaria CMS1 mouthrinse
Number of subjects: 0
Study 14998732 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 45
Study 14998732 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed stress management
Number of subjects: 45
Study 14998732 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 45
Study 11716192 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2.5 mg, i.e., 100,000 IU) administered orally at three specific periods (end of September, November, and January)
Number of subjects: 54
Study 11716192 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D3 treatment)
Number of subjects: 54
Study 9173971 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive breathing trials with supplemental oxygen at loads of 35, 50, 75, and 90% of maximal inspiratory pressure (MIP)
Number of subjects: 6
Study 9173971 — intervention group
Group type: COMPARATOR
Intervention: Resistive breathing trials without supplemental oxygen at loads of 35, 50, 75, and 90% of maximal inspiratory pressure (MIP)
Number of subjects: 6
Study 8424419 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg over 20 min)
Number of subjects: 0
Study 8424419 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 2434546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol 17-propionate cream applied twice daily for 1 week
Number of subjects: 17
Study 2434546 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control applied twice daily for 1 week
Number of subjects: 17
Study 2434546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol 17-propionate cream
Number of subjects: 17
Study 28110564 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diet and exercise programmes
Number of subjects: 409
Study 28110564 — intervention group
Group type: COMPARATOR
Intervention: Standard written advice (Control)
Number of subjects: 409
Study 27302672 — intervention group
Group type: EXPERIMENTAL
Intervention: Chungkookjang
Number of subjects: 120
Study 27302672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 25054553 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg·kg‐1)
Number of subjects: 6
Study 25054553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 25054553 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 6
Study 22838225 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular block
Number of subjects: 102
Study 22838225 — intervention group
Group type: COMPARATOR
Intervention: Maxillary infiltration
Number of subjects: 102
Study 20831379 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual methods (narrow phonetic transcription; prosody‐voice coding)
Number of subjects: 10
Study 20831379 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic analysis methods
Number of subjects: 10
Study 18412782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry tablet insertion of vaginal misoprostol (400 microg)
Number of subjects: 148
Study 18412782 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel form of vaginal misoprostol (400 microg)
Number of subjects: 148
Study 12377965 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour daily infusion of ara-C 500 mg/m(2)/d and 2-CdA 9 mg/m(2)/d (arm A)
Number of subjects: 49
Study 12377965 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ara-C 500 mg/m(2)/d and 2-CdA 9 mg/m(2)/d (arm B)
Number of subjects: 49
Study 12377965 — intervention group
Group type: EXPERIMENTAL
Intervention: After two courses of DAV (arm A)
Number of subjects: 49
Study 12377965 — intervention group
Group type: EXPERIMENTAL
Intervention: After two courses of DAV (arm B)
Number of subjects: 49
Study 12377965 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of 2-CdA with ara-C
Number of subjects: 49
Study 12377965 — intervention group
Group type: COMPARATOR
Intervention: Toxicity incidence between treatment arms
Number of subjects: 49
Study 10085671 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Granisetron 1 mg
Number of subjects: 120
Study 10085671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 7800169 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 300
Study 7800169 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 300
Study 3142367 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of muroctasin
Number of subjects: 131
Study 3142367 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of muroctasin
Number of subjects: 131
Study 3142367 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 131
Study 30272231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg) once daily for 14 days
Number of subjects: 20
Study 30272231 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/cobicistat (800/150 mg) once daily for 14 days
Number of subjects: 20
Study 30272231 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir/darunavir/cobicistat (DTG/DRV/COBI) once daily
Number of subjects: 20
Study 28339286 — intervention group
Group type: EXPERIMENTAL
Intervention: Transosseous hardware-free suture repair
Number of subjects: 69
Study 28339286 — intervention group
Group type: COMPARATOR
Intervention: Single-row anchor fixation
Number of subjects: 69
Study 28339286 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 69
Study 25939897 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily
Number of subjects: 405
Study 25939897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 22692116 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration and low intensity general warm-up (LDLI; 15 minutes at 40% V[Combining Dot Above]O2max)
Number of subjects: 16
Study 22692116 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration and moderate intensity general warm-up (LDMI; 15 minutes at 70% V[Combining Dot Above]O2max)
Number of subjects: 16
Study 22692116 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration and moderate intensity (SDMI; 5 minutes at 70% V[Combining Dot Above]O2max)
Number of subjects: 16
Study 22692116 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration and low intensity (SDLI; 5 minutes at 40% V[Combining Dot Above]O2max)
Number of subjects: 16
Study 22692116 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL) no-GWU condition
Number of subjects: 16
Study 21394686 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgingival antibacterial photodynamic therapy (PDT)
Number of subjects: 19
Study 21394686 — intervention group
Group type: COMPARATOR
Intervention: Control site rinsed with ringer solution
Number of subjects: 19
Study 18086243 — intervention group
Group type: EXPERIMENTAL
Intervention: UV‐Index (UV‐I) sensor intervention group
Number of subjects: 91
Study 18086243 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 17031264 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dipyridamole 200 mg twice daily for 24 weeks
Number of subjects: 44
Study 17031264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 12974986 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemifitide (re-treatment)
Number of subjects: 27
Study 12974986 — intervention group
Group type: COMPARATOR
Intervention: Nemifitide (initial treatment)
Number of subjects: 27
Study 10950443 — intervention group
Group type: COMPARATOR
Intervention: Leg delta50 (legs only)
Number of subjects: 11
Study 10950443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ldelta50 + A25 (leg delta50 plus light arm cranking at 25% of arm lactate threshold)
Number of subjects: 11
Study 9058575 — intervention group
Group type: EXPERIMENTAL
Intervention: Changed memory condition (children were touched in a specific way)
Number of subjects: 160
Study 9058575 — intervention group
Group type: COMPARATOR
Intervention: Planted memory condition (children were suggested a different touch)
Number of subjects: 160
Study 9058575 — intervention group
Group type: COMPARATOR
Intervention: Erased memory condition (children were suggested no touch at all)
Number of subjects: 160
Study 8138868 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Number of subjects: 64
Study 8138868 — intervention group
Group type: COMPARATOR
Intervention: School Reintegration
Number of subjects: 64
Study 31521119 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg
Number of subjects: 345
Study 31521119 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 345
Study 31521119 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (Control)
Number of subjects: 345
Study 29709789 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Number of subjects: 31
Study 29709789 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 31
Study 27046390 — intervention group
Group type: EXPERIMENTAL
Intervention: 40Gy/15 fractions (3-weeks)
Number of subjects: 190
Study 27046390 — intervention group
Group type: EXPERIMENTAL
Intervention: 27Gy/5 fractions (1-week)
Number of subjects: 190
Study 27046390 — intervention group
Group type: EXPERIMENTAL
Intervention: 26Gy/5 fractions (1-week)
Number of subjects: 190
Study 25318999 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 255
Study 25318999 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin combined with hydroxychloroquine
Number of subjects: 255
Study 25318999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 22661752 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. MgSO(4) at a dose of 50 mg kg(‐1) diluted in 100 ml 0.9% saline solution followed by 15 mg kg(‐1) h(‐1) for 6 h
Number of subjects: 45
Study 22661752 — intervention group
Group type: COMPARATOR
Intervention: Saline at the same volume [mean (sd) 64 (10) ml]
Number of subjects: 45
Study 20402551 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg
Number of subjects: 85
Study 20402551 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine 60 mg
Number of subjects: 85
Study 18334918 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 expressers (n=26)
Number of subjects: 136
Study 18334918 — intervention group
Group type: COMPARATOR
Intervention: CYP3A5 nonexpressers (n=110)
Number of subjects: 136
Study 17159695 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS)
Number of subjects: 30
Study 17159695 — intervention group
Group type: COMPARATOR
Intervention: Minor head trauma patients without hematoma (control group)
Number of subjects: 30
Study 10801253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg daily for 6 months
Number of subjects: 0
Study 10801253 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8716706 — intervention group
Group type: EXPERIMENTAL
Intervention: Precautionary education (group and individual education)
Number of subjects: 0
Study 1570909 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed charts
Number of subjects: 0
Study 1570909 — intervention group
Group type: COMPARATOR
Intervention: Blank charts
Number of subjects: 0
Study 3874746 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush supplemented with toothpick for interproximal subgingival cleaning, with instruction to use bleeding as an interpretive device for health.
Number of subjects: 36
Study 3874746 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush supplemented with toothpick for interproximal subgingival cleaning, with identical instruction in toothpick technique but without using bleeding as an interpretive device.
Number of subjects: 36
Study 3874746 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush only (control group).
Number of subjects: 36
Study 30843231 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser (PDL) treatment
Number of subjects: 14
Study 30843231 — intervention group
Group type: COMPARATOR
Intervention: Sham control (no PDL treatment)
Number of subjects: 14
Study 29681248 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Intervention Group (CIG)
Number of subjects: 349
Study 29681248 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Intervention Group (MIG)
Number of subjects: 349
Study 29681248 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 349
Study 26656679 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 0
Study 26656679 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 0
Study 26656679 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle changes
Number of subjects: 0
Study 26656679 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 0
Study 26656679 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 0
Study 26656679 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV and lifestyle changes
Number of subjects: 0
Study 26656679 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV and CPAP
Number of subjects: 0
Study 23724796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 50% maximal heart rate reserve (HRR)
Number of subjects: 18
Study 23724796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 75% maximal heart rate reserve (HRR)
Number of subjects: 18
Study 22036837 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised multi-factorial lifestyle intervention
Number of subjects: 6091
Study 22036837 — intervention group
Group type: COMPARATOR
Intervention: Control group (questionnaires)
Number of subjects: 6091
Study 20426840 — intervention group
Group type: EXPERIMENTAL
Intervention: MEND (Mind Exercise Nutrition Do It!) program delivered to parents of children aged 2-4 years, consisting of ten 90-minute group workshops focusing on nutrition and physical activity.
Number of subjects: 200
Study 20426840 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (not receiving the MEND program).
Number of subjects: 200
Study 17973713 — intervention group
Group type: EXPERIMENTAL
Intervention: Study oil (A)
Number of subjects: 71
Study 17973713 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral oil (B)
Number of subjects: 71
Study 17973713 — intervention group
Group type: COMPARATOR
Intervention: No intervention (C)
Number of subjects: 71
Study 16298068 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg dexamethasone
Number of subjects: 20
Study 16298068 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 12087350 — intervention group
Group type: EXPERIMENTAL
Intervention: S21402 (250 mg)
Number of subjects: 10
Study 12087350 — intervention group
Group type: COMPARATOR
Intervention: Captopril (50 mg)
Number of subjects: 10
Study 10210235 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation
Number of subjects: 89
Study 10210235 — intervention group
Group type: COMPARATOR
Intervention: Conventional community care
Number of subjects: 89
Study 7872387 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fibronectin ophthalmic solution (3.5 mg/ml)
Number of subjects: 65
Study 7872387 — intervention group
Group type: COMPARATOR
Intervention: Vehicle drops from the fibronectin solution
Number of subjects: 65
Study 7872387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 2404368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime 500 mg twice daily for five days
Number of subjects: 39
Study 2404368 — intervention group
Group type: COMPARATOR
Intervention: Moxalactam 500 mg twice daily for five days
Number of subjects: 39
Study 358727 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical blocks administered to PGF2alpha-treated patients
Number of subjects: 100
Study 358727 — intervention group
Group type: COMPARATOR
Intervention: No paracervical blocks administered to PGF2alpha-treated patients
Number of subjects: 100
Study 358727 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical blocks administered to saline-treated patients
Number of subjects: 100